Available data support the safety and effectiveness of the Johnson & Johnson COVID-19 vaccine for emergency use authorization as a booster dose in individuals aged 18 and older at least two months after an initial single dose, the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted 19-0 today. The committee also discussed early data from a study sponsored by the National Institute of Allergy and Infectious Diseases evaluating the immunogenicity of each of the three authorized COVID-19 vaccines following immunization with the same or a different booster dose.

The committee yesterday voted unanimously to recommend boosters for previous Moderna recipients age 65 and older, plus individuals age 18-64 if they are at high risk of severe COVID-19 or whose frequent institutional or occupational exposure puts them at high risk of serious complications, including severe COVID-19. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices will consider the recommendations next week. FDA last month amended Pfizer’s emergency use authorization for its COVID-19 vaccine to allow for an additional, booster dose for certain individuals.

 

Related News Articles

News
The U.S. District Court for the Eastern District of Missouri today granted a preliminary injunction preventing the Centers for Medicare & Medicaid Services…
Headline
A two-dose series of the Pfizer-BioNTech COVID-19 vaccine was 100% effective against COVID-19 in 12-15 year olds more than four months after the second dose in…
Headline
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., Friday expanded eligibility for COVID-19 booster shots to include all adults…
Headline
The Food and Drug Administration today authorized a single booster dose of the Pfizer or Moderna COVID-19 vaccine for all individuals aged 18 or older at…
Headline
The federal government will purchase 10 million treatment courses of the COVID-19 oral antiviral Paxlovid from Pfizer if the Food and Drug Administration…
Headline
The Occupational Safety and Health Administration has suspended activities related to implementation and enforcement of its Emergency Temporary Standard on…